Financial releases

Strengthening of pharma skills within the Crossject supervisory board

First-half 2018 results and business update

Crossject announces the principle of the free issue and allotment of warrants to the shareholders and new € 2.5 million convertible bond

Business update may 2018

Annual 2017 results and business update

Financial calendar 2018

Free allotment of warrants to the shareholders and issue of a convertible bond

FDA grants orphan-drug designation to ZENEO® Midazolam

Business update

Interim 2017 results and business update